Rx Pharma
Rx Pharma

India has started manufacturing 38 APIs in past 1.5 years: Minister of Health and Family Welfare of India

Mansukh Mandaviya - Minister of Health and Family Welfare of India

India has started manufacturing 38 active pharmaceutical Ingredients or APIs, in the last one and a half years on which it was import-dependent, under the production-linked incentive (PLI) scheme for the sector, Union Health Minister Mansukh Mandaviya said here Saturday.

Mandaviya said that the 2017 border standoff with China at Doklam triggered India to rethink its self-reliant strategy regarding active pharma components as it was dependent on just one country for the import of 95 per cent of APIs for the formulation industry.

Also Read...

The health minister was speaking at the inaugural event of the Healthcare Summit organised at the Indian Institute of Management Ahmedabad (IIMA).

“Through the PLI scheme, we tried to ensure that the country does not have to import 54 APIs from abroad and our formulation industry gets APIs domestically. I am happy to share that in just a year and a half, India has started manufacturing 38 APIs, which is an example of Atmanirbhar Bharat,” he said.

The government has announced a Rs 15,000-crore PLI scheme for the pharmaceutical sector, he said.

The first priority for this government to make healthcare accessible and affordable in rural areas was to address the requirement of doctors, he said.

“In the last nine years, the number of MBBS seats has increased from 52,000 to 1,07,000. This year, we have given approval to 54 new medical colleges,” Mandaviya said.

The Minister of Health and Family Welfare and Chemicals and Fertilizers said COVID-19 pandemic inspired them for rethinking, replanning and redevelopment in the healthcare sector.

“There was never a shortage of brainpower and manpower in India. The thing is to understand the dreams in the eyes of the youth and open pathways and identify opportunities to make them fulfil,” he said.

The minister said research and innovation (R&D) is the biggest requirement for the country.

“Lack of innovation and research negatively impacts Atmanirbharta (self-reliance). If we do not have our own research, we cannot fulfil our requirements on time and will be forced to purchase items at a higher price,” he said, adding that his government has taken steps to encourage private domestic pharma companies to increase spending on R&D.

IIMA chairman Pankaj Patel and director Bharat Bhasker were also present at the event organised by the premier institute’s Centre of Management of Health Services (CMHS) and IIMA Healthcare Alumni Special Interest Group (SIG).

The summit featured two tracks, each focused on a crucial aspect of healthcare innovation, with panel discussions and competition for healthcare start-ups.

Source : The Economic Time, https://economictimes.indiatimes.com/

Share this post:
Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *

Subscribe Our Newsletter to Get Latest News and Articles Notification on Your Emails.